Pallas Capital Advisors LLC Buys 9,972 Shares of Bristol Myers Squibb Company $BMY

Pallas Capital Advisors LLC raised its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 44.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,407 shares of the biopharmaceutical company’s stock after purchasing an additional 9,972 shares during the period. Pallas Capital Advisors LLC’s holdings in Bristol Myers Squibb were worth $1,462,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of BMY. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth about $25,000. Harbor Capital Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the period. Total Investment Management Inc. acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $38,000. Twin Peaks Wealth Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $40,000. Finally, Mark Sheptoff Financial Planning LLC raised its stake in shares of Bristol Myers Squibb by 233.3% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 700 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Guggenheim reissued a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average price target of $59.20.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $60.28 on Wednesday. The stock has a 50-day simple moving average of $55.70 and a 200 day simple moving average of $49.72. The stock has a market capitalization of $122.76 billion, a price-to-earnings ratio of 17.47, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the firm posted $1.67 earnings per share. The company’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.